WSFA 12 News Montgomery, AL |Clinical trials update: Nov. 3, 2009

Clinical trials update: Nov. 3, 2009

(HealthDay News) -- Here are the latest clinical trials, courtesy of ClinicalConnection.com:

Postmenopausal Osteoporosis Prevention

This study will evaluate an investigational drug to prevent postmenopausal osteoporosis and treat menopausal symptoms while ensuring uterine lining safety.

The research site is in Chicago, Ill.

More information

Please see http://www.clinicalconnection.com/clinical_trials/condition/osteoporosis.aspx.

-----

Insomnia

This study for people aged 18 to 85 will evaluate an investigational drug for insomnia. Participants will receive study related medical care, study medication, and compensation up to $800.

The research site is in Glendale, Calif.

More information

Please see http://www.clinicalconnection.com/clinical_trials/condition/insomnia.aspx.

-----

Frequent Night Time Urination (Nocturia)

This study will evaluate an investigational treatment for frequent night time urination. Participants will receive study related care, investigational medication and may qualify for travel compensation.

The research site is in Pinellas Park, Fla.

More information

Please see http://www.clinicalconnection.com/clinical_trials/condition/nocturia.aspx.

-----

Copyright 2009 ClinicalConnection.com. All rights reserved.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
Powered by WorldNow
All content © Copyright 2000 - 2009 WorldNow and WSFA, a Raycom Media Station.
All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.